VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Jan. 31, 2007) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today the Company’s key milestones for 2007 that include the completion of two ongoing Phase II human efficacy trials and the initiation of the recently announced Phase II human efficacy trial in a collaboration with the National Institute of Mental Health funded project TURNS (Treatment Unit for Research of Neurocognition in Schizophrenia).
